Ablynx Ups Profile Stateside With $200m Nasdaq Listing

Success in the clinic with caplacizumab for aTTP and a big IPO in the USA has put the Belgium-headquartered group in the spotlight.

Dollar Airplane_1200
Flying high: Ablynx IPO in the US has been a success • Source: Shutterstock

Fresh from its clinical success with caplacizumab, Ablynx NV has priced its initial US public offering totaling $200m, propelling the company's market capitalization over the €1bn mark.

The Belgium-headquartered group has listed on the Nasdaq after selling 11.4 million American Depositary Shares (ADS) priced at $17.50 each....

More from Business

Novartis Upbeat Even With Entresto Expiry Looming

 
• By 

Swiss major confident that new oncology drugs will fill revenue gap.

China Sentences Astellas Employee To 3.5 Years In Prison On Spy Charges

 
• By 

An employee of Astellas faces three and a half years in prison after sentencing by a court in China on espionage charges.

Sarepta Restructures, Cuts 500 Jobs As Elevidys-Related Deaths Impact Sales

 
• By 

After a second quarter of declining Elevidys sales following two deaths of DMD patients treated with the gene therapy, Sarepta is cutting costs to fund remaining programs and meet debt requirements.

Deal Watch: Debiopharm Takes On Precision Oncology Drug From Repare Collab

 

Plus deals involving Novartis/Sironax, Neuraxpharm/Dizlin, Recursion/RallyBio, MaaT/Clinigen, Future Pak/Theratechnologies, BerGenBio/Oncoinvent, Xoma/Turnstone and more.

More from Scrip